SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
___________________
Date of Report (Date of earliest event reported) September 18, 1998
BIOCONTROL TECHNOLOGY, INC.
(Exact name of registrant as specified in its charter)
Pennsylvania 0-10822 25-1229323
(State of other jurisdiction (Commission File Number) (IRS Employer
of incorporation Identification No.)
300 Indian Springs Road, Indiana, Pennsylvania 15701
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (412) 349-1811
_________________________________________________________________
(Former name or former address,
if changes since last report.)
Item 1. Change in Control of Registrant.
Not applicable.
Item 2. Acquisition or Disposition of Assets.
Not applicable.
Item 3. Bankruptcy or Receivership.
Not applicable.
Item 4. Changes in Registrant's Certifying Accountant
Not applicable.
Item 5. Other Events.
Biocontrol Technology, Inc. (Nasdaq:BICO) subsidiary
Diasense, Inc. today announced that it continues to
receive orders for the Diasensor 1000 from its European
distributor, EuroSurgical, LTD. Three additional orders for
immediate shipment have recently been received, bringing the
total sales to seven. Thus far, the devices, which sell for
US$9,000, have been sold in the UK, Germany, and Portugal.
EuroSurgical has an agreement for exclusive marketing rights in
the United Kingdom but can also sell outside the UK.
Item 6. Resignation of Registrant's Directors.
Not Applicable.
Item 7. Financial Statement, Pro Forma Financial Information and Exhibits.
(a) Financial Statements and Businesses Acquired
Not Applicable.
(b) Pro Forma Financial Information
Not Applicable.
(c) Exhibits - Press Release.
SIGNATURES
Pursuant to the requirement of the Securities Exchange Act
of 1934, the Registrant has duly caused this Report to be signed
on its behalf by the undersigned hereunto duly authorized.
BIOCONTROL TECHNOLOGY, INC.
by /s/ Fred E. Cooper
Fred E. Cooper, CEO
DATED: September 18, 1998
BIOCONTROL TECHNOLOGY, INC.
2275 Swallow Hill Road, Building 2500
Pittsburgh, PA 15220
Investors Media
Diane McQuaide Susan Taylor
1.412.429.0673 phone 1.412.279.9455 phone
1.412.279.9690 fax 1.412.279.9447 fax
BIOCONTROL SUBSIDIARY, DIASENSE, INC., CONTINUES DIASENSOR
SALES
Pittsburgh, PA - September 18, 1998 - Biocontrol Technology, Inc.
(Nasdaq:BICO) subsidiary Diasense, Inc. today announced that it
continues to receive orders for the Diasensor1000 from its
European distributor, EuroSurgical, Ltd. Three additional orders
for immediate shipment have recently been received, bringing the
total sales to seven. Thus far, the devices, which sell for
US$9,000, have been sold in the UK, Germany, and Portugal.
In order to assure the best service possible of these
initial devices, the first noninvasive glucose sensors ever
available to diabetics, EuroSurgical is proceeding conservatively
but reports that inquiries regarding the Diasensor 1000 continue
to increase. EuroSurgical has an agreement for exclusive
marketing rights in the United Kingdom but can also sell outside
the UK.
The Diasensor 1000 received European marketing approval just
two months ago.
Biocontrol Technology, Inc. (www.bico.com) has its corporate
offices in Pittsburgh, PA and is involved in the development and
manufacture of biomedical devices and environmental products.
Also located in Pittsburgh, PA, Diasense is a subsidiary of
Biocontrol Technology and owns the patent, marketing and
distribution rights to the sensor. Biocontrol has the exclusive
rights to the research and development and manufacturing of the
Sensor.
This press release contains forward looking statements and shareholders
and potential investors are cautioned that such statements are predictions
and actual events or results may vary significantly.
